{ "ok": true, "cik": "921299", "ticker": "KYNB", "name": "KYNTRA BIO, INC.", "filings": [ { "form": "8-K", "filed": "2026-10-01", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/921299/000119312526409819/0001193125-26-409819-index.htm" }, { "form": "8-K", "filed": "2026-08-31", "items": [ "1.01 Entry into a Material Definitive Agreement", "2.03 Creation of a Direct Financial Obligation", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/921299/000119312526377059/0001193125-26-377059-index.htm" }, { "form": "10-Q", "filed": "2026-08-13", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/921299/000119312526349183/0001193125-26-349183-index.htm" }, { "form": "8-K", "filed": "2026-08-13", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/0001193125-26-349141-index.htm" }, { "form": "8-K", "filed": "2026-06-16", "items": [ "5.07 Submission of Matters to a Vote of Security Holders" ], "url": "https://www.sec.gov/Archives/edgar/data/921299/000119312526271449/0001193125-26-271449-index.htm" }, { "form": "8-K", "filed": "2026-06-09", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/921299/000119312526264000/0001193125-26-264000-index.htm" } ], "events12m": 11, "healthWatch": { "window": "last 12 months", "since": "2025-10-02", "signals": [ { "code": "3.01", "label": "Exchange listing notice or transfer", "count": 1, "latest": { "filed": "2026-04-09", "url": "https://www.sec.gov/Archives/edgar/data/921299/000119312526149624/0001193125-26-149624-index.htm" } }, { "code": "5.02", "label": "Director or officer change", "count": 1, "latest": { "filed": "2026-10-01", "url": "https://www.sec.gov/Archives/edgar/data/921299/000119312526409819/0001193125-26-409819-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000921299.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=921299" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up KYNTRA BIO, INC. ($KYNB). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-10-01. 11 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 6440000, "revenueGrowth1y": -0.7825866783700752, "revenueGrowthPerYear": -0.5932647314451358, "yearsOfData": 5, "operatingMargin": -7.126552795031056, "operatingMarginPrior": -5.078018973025894, "netMargin": 28.48633540372671, "operatingCashFlow": -4774000, "capitalSpending": 38000, "freeCashFlow": -4812000, "researchAndDevelopment": 23517000, "researchShareOfRevenue": 3.6517080745341617, "cash": 47872000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 235309000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 140734000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 46803000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 29621000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 6440000 } ], "totalEquity": -30038000, "totalAssets": 119594000, "equityRatio": -0.251166446477248, "returnOnEquity": null, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": 45.37, "sharesOutstanding": 4043000, "bookValuePerShare": -7.429631461785803, "revenuePerShare": 1.5928765767994064, "range80": { "low": 800331.4235388951, "high": 4161561.236440993, "baseline": 1851803.0284808173, "n": 2483, "band": "b000", "bandLabel": "under $50M", "method": "v4.1", "credibility": 0.5714285714285714, "growthYears": 5, "ownVolatility": 0.49430287364950576, "classVolatility": 0.3000583276631395, "volatility": 0.42214525658366814 }, "ifPaceHeld": { "low": 800331.4235388951, "high": 4161561.236440993 } }, "edgarette": "🔖 Exposure: revenue $6.4M (FY2025). Experience: revenue down 78.3% on the year, down 59.3% a year over 4 years; operating margin -712.7%, down from -507.8%. Soundness: equity -25.1% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $800K and $4.2M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $715K to $4.7M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -712.7% against a -3.8% median; growth -78.3% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Kyntra Bio (KYNB) saw revenue fall 78.3% in FY2025 to $6 million, operating margin -713% against a -3.8% median for pharmaceutical preparations, equity -25.1% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
KYNTRA BIO, INC. against its own record and its peers
Operating marginPeer median -3.8%-712.7%Revenue, on the yearPeer median 13.7%-78.3%Equity of assetsPeer median 40.3%-25.1%Gold tick: the median of 118–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 9, "hits": 2, "rate": 0.2222222222222222, "method": "v4", "byYear": { "2017": [ 0, 1 ], "2018": [ 0, 1 ], "2019": [ 1, 1 ], "2020": [ 0, 1 ], "2021": [ 0, 1 ], "2022": [ 0, 1 ], "2023": [ 0, 1 ], "2024": [ 1, 1 ], "2025": [ 0, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-10-02T14:03:50.266Z", "hash": "5786e2739b36c343", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Kyntra Bio (KYNB) saw revenue fall 78.3% in FY2025 to $6 million, operating margin -713% against a -3.8% median for pharmaceutical preparations, equity -25.1% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 6440000, "totalDebt": null, "cash": 47872000 }, "experience": { "revenueGrowth1y": -0.7825866783700752, "revenueGrowthPerYear": -0.5932647314451358, "operatingMargin": -7.126552795031056, "operatingMarginPrior": -5.078018973025894, "netMargin": 28.48633540372671, "freeCashFlow": -4812000 }, "soundness": { "equityRatio": -0.251166446477248, "returnOnEquity": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "healthWatch": { "window": "last 12 months", "since": "2025-10-02", "signals": [ { "code": "3.01", "label": "Exchange listing notice or transfer", "count": 1, "latest": { "filed": "2026-04-09", "url": "https://www.sec.gov/Archives/edgar/data/921299/000119312526149624/0001193125-26-149624-index.htm" } }, { "code": "5.02", "label": "Director or officer change", "count": 1, "latest": { "filed": "2026-10-01", "url": "https://www.sec.gov/Archives/edgar/data/921299/000119312526409819/0001193125-26-409819-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": { "low": 800331.4235388951, "high": 4161561.236440993, "baseline": 1851803.0284808173, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 2483, "sizeBand": "under $50M", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341, "coverageAllYears": 0.6904374799277399, "stressCoverageAllYears": 0.819004992974709, "outcomeYears": [ 2019, 2025 ] }, "credibility": { "weightOnOwnRecord": 0.571, "growthYears": 5, "ownVolatility": 0.49430287364950576, "classVolatility": 0.3000583276631395, "pricedVolatility": 0.42214525658366814, "k": 3 }, "stress": { "low": 714777.0626335037, "high": 4678020.3847688185, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 9, "hits": 2, "rate": 0.2222222222222222, "method": "v4", "byYear": { "2017": [ 0, 1 ], "2018": [ 0, 1 ], "2019": [ 1, 1 ], "2020": [ 0, 1 ], "2021": [ 0, 1 ], "2022": [ 0, 1 ], "2023": [ 0, 1 ], "2024": [ 1, 1 ], "2025": [ 0, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-10-02T14:03:50.266Z", "hash": "5786e2739b36c343", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000921299.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=921299" }, "speedCash": { "fiscalYear": 2025, "cashConversion": -0.7413, "growth3y": -0.6423, "volatility": 0.4943, "paysDividend": false, "raisedDividend": false, "equityRatio": -0.2512, "quadrant": { "code": "sj", "label": "Slow and jumpy", "plain": "growing slower than its size class, with revenue that swings more" }, "compass": { "code": "fading", "inside": "Turns -74.1% of revenue into operating cash; revenue shrinking 64.2% a year over three years; no common dividend; liabilities exceed assets.", "outside": "Among under $50M companies: 37th percentile for cash, 2nd for growth.", "emoji": "🍂", "label": "Fading", "plain": "slow and jumpy, lagging its peers" }, "band": "under $50M", "cashPctInClass": 37, "growthPctInClass": 2, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "balance", "text": "liabilities exceed assets (often from years of share buybacks, not always distress)" }, { "key": "slowjumpy", "text": "slow and jumpy: growing slower than its size class, with revenue that swings more" }, { "key": "cash", "text": "operating cash flow was negative" }, { "key": "range", "text": "revenue is hard to predict: its 80% range is ±68%" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 4, "name": "Rotting at the dock", "plain": "four or more warning signs" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": -4774000, "investing": 35419000, "financing": -86028000, "capitalSpending": 38000, "free": -4812000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": -82232000, "free": -87418000 }, { "fiscalYearEnd": "2022-12-31", "operating": -145933000, "free": -149674000 }, { "fiscalYearEnd": "2023-12-31", "operating": -315021000, "free": -317540000 }, { "fiscalYearEnd": "2024-12-31", "operating": -137999000, "free": -138265000 }, { "fiscalYearEnd": "2025-12-31", "operating": -4774000, "free": -4812000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 47872000, "shortTerm": 41106000, "longTerm": 20160000, "equityHoldings": null, "totalAssets": 119594000, "ladder": null, "currentRatio": 3.39, "unrealizedGain": 38000, "unrealizedLoss": 0, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": { "fiscalYear": 2025, "cashConversion": -0.7413, "growth3y": -0.6423, "volatility": 0.4943, "paysDividend": false, "raisedDividend": false, "equityRatio": -0.2512, "quadrant": { "code": "sj", "label": "Slow and jumpy", "plain": "growing slower than its size class, with revenue that swings more" }, "compass": { "code": "fading", "inside": "Turns -74.1% of revenue into operating cash; revenue shrinking 64.2% a year over three years; no common dividend; liabilities exceed assets.", "outside": "Among under $50M companies: 37th percentile for cash, 2nd for growth.", "emoji": "🍂", "label": "Fading", "plain": "slow and jumpy, lagging its peers" }, "band": "under $50M", "cashPctInClass": 37, "growthPctInClass": 2, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "balance", "text": "liabilities exceed assets (often from years of share buybacks, not always distress)" }, { "key": "slowjumpy", "text": "slow and jumpy: growing slower than its size class, with revenue that swings more" }, { "key": "cash", "text": "operating cash flow was negative" }, { "key": "range", "text": "revenue is hard to predict: its 80% range is ±68%" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 4, "name": "Rotting at the dock", "plain": "four or more warning signs" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": -4774000, "investing": 35419000, "financing": -86028000, "capitalSpending": 38000, "free": -4812000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": -82232000, "free": -87418000 }, { "fiscalYearEnd": "2022-12-31", "operating": -145933000, "free": -149674000 }, { "fiscalYearEnd": "2023-12-31", "operating": -315021000, "free": -317540000 }, { "fiscalYearEnd": "2024-12-31", "operating": -137999000, "free": -138265000 }, { "fiscalYearEnd": "2025-12-31", "operating": -4774000, "free": -4812000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 47872000, "shortTerm": 41106000, "longTerm": 20160000, "equityHoldings": null, "totalAssets": 119594000, "ladder": null, "currentRatio": 3.39, "unrealizedGain": 38000, "unrealizedLoss": 0, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }